Funding for this research was provided by:
Bristol Myers Squibb (CA184-400)
Varian Medical Systems
Text and Data Mining valid from 2019-09-04
Received: 28 May 2019
Accepted: 27 August 2019
First Online: 4 September 2019
Ethics approval and consent to participate
: This post-hoc analysis of single-institution clinical trials was reviewed and approved by the MD Anderson Cancer Center institutional review board.
: All data presented in this study was collected from clinical trials which included patient consent for publication.
: ICG, MA, JVH and DSH have received research grants from Bristol-Myers Squibb. JWW, ICG, JVH, and DSH also receive research funding from Merck. MA receives research funding from Novartis and Lilly. DSH and JWW are founders and have ownership interest in OncoResponse and MolecularMatch. All other authors declare no conflicts of interest. JWW reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck , Nanobiotix, Mavu Pharma and Checkmate Pharmaceuticals. JWW serves on the scientific advisory board for RefleXion Medical, MolecularMatch, OncoResponse, CheckMate, Mavu Pharmaceuticals, Alpine Immune Sciences. He is co-founder of Healios Oncology, MolecularMatch, and OncoResponse and serves as an advisor to Astra Zeneca, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. JWW has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM.